Clinical trials: Menopausal Women
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD
Menopause Syndrome, Menopause
A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.
- Conditions
- Menopause Syndrome, Menopause, Hot Flashes
- Trial name
- NCT06385795
- Testing
- NOE-115
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Noema Pharma AG
Vulvovaginal Atrophy
Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women
This study evaluates the efficacy and safety of hyaluronic acid derivative based vaginal pessaries for the treatment of symptoms of vulvo-vaginal atrophy in post-menopausal women.
- Trial name
- NCT03557398
- Testing
- Hydeal-D vaginal pessaries
- Where
- 2 sites in Slovakia
- Volunteers
- 40 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Menopause
Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms
The aim of the study is to investigate effects of daily intake of Nordic Kudzu for 28 days in 5 groups of 10 menopausal women with symptoms.
- Trial name
- KUDZU-01 (NCT04552106)
- Testing
- 3 caps x3/day, 3 caps x2/day, 2 caps x3/day
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Nordic Bioscience A/S
Osteoporosis
Open Label Extension Study of PREOS
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human…
- Trial name
- OLES (NCT00172133)
- Testing
- ALX1-11 (drug)
- Where
- 132 sites in United States, Argentina and 6 more
- Volunteers
- 1,683 people
- Sponsor
- Shire
Healthy Female Participants, Postmenopause
A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participants
The purpose of this study is to compare the bioequivalence and adhesion performance of a test estradiol/levonorgestrel transdermal delivery system (TDS) with the reference product, Climara Pro® (estradiol/levonorgestrel…
- Trial name
- NCT07851649
- Testing
- Test Estradiol/Levonorgestrel Transdermal Delivery System, Climara Pro® (Estradiol/Levonorgestrel Transdermal System)
- Where
- India
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
ATAC - Arimidex, Tamoxifen Alone or in Combination
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
- Trial name
- NCT00849030
- Testing
- Anastozole (Arimidex), Tamoxifen (Nolvadex)
- Volunteers
- 9,358 people
- Sponsor
- AstraZeneca
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.
Menopause Hot Flashes
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- NCT03291067
- Testing
- MT-8554 1mg, MT-8554 5mg, MT-8554 10mg
- Where
- 63 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tanabe Pharma America, Inc.
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two…
- Trial name
- BLOOM (NCT00612742)
- Testing
- testosterone gel
- Where
- 149 sites in United States, Canada
- Volunteers
- 3,656 people
- Sponsor
- BioSante Pharmaceuticals
Menopause, Menopause Related Conditions
World Digital Detox Program for Enhancing Women's Health & Well-being
The concept of a digital detox, involving a deliberate reduction or elimination of digital device usage, has emerged as a potential strategy to mitigate the adverse effects of technology on mental and physical well-being.
- Conditions
- Menopause, Menopause Related Conditions, Psychological Stress
- Trial name
- NCT06154798
- Testing
- World Digital Detox Women's Health Program
- Where
- India
- Volunteers
- 73 people
- Sponsor
- Innowage Limited
Menopause, Sleep Disturbance
Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes
A randomized, double-blind, placebo-controlled, direct-to-consumer trial assessing the impact of health and wellness products on hormonal health and associated health outcomes in women with menopausal health issues
- Conditions
- Menopause, Sleep Disturbance, Anxiety, Depression
- Trial name
- NCT06749288
- Testing
- Radicle Revive Active Study Product 4.1 Usage
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
Vasomotor Symptoms
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
This study is for women in menopause who have moderate to severe hot flashes. It is for women who are unable to use hormone replacement therapy (HRT). Menopause, a normal part of life, is the time after a woman's last period.
- Trial name
- Daylight (NCT05033886)
- Testing
- fezolinetant
- Where
- 69 sites in Belgium, Canada and 14 more
- Volunteers
- 453 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Ovarian Cancer
Optimal Timing of BR55 CEUS of the Ovaries
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal…
- Trial name
- NCT04248153
- Testing
- BR55
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bracco Diagnostics, Inc
Postmenopause
Endometrial Safety Study
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
- Trial name
- NCT00522873
- Testing
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 662 people
- Sponsor
- Bayer
Atrophy, Vaginal Diseases
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.
- Trial name
- NCT00729469
- Testing
- Ospemifene 60 mg
- Volunteers
- 919 people
- Sponsor
- Shionogi
Vaginismus, Vaginal Atrophy
Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
- Conditions
- Vaginismus, Vaginal Atrophy, Menopause
- Trial name
- NCT06564883
- Testing
- 0.20% sodium hyaluronate gel
- Volunteers
- 45 people
- Sponsor
- Biolab Sanus Farmaceutica
Skin Aging, Dry Skin
Human In Use Test of GINPI-HP-004 in Healthy Adults
The main objective of this study was to confirm skin acceptability of the product GINPI REF. GINPI BATCH: 10/06/2024 applied under normal use conditions in healthy female adult volunteers, under gynecological control, by means of…
- Trial name
- NCT07533474
- Testing
- Depigmentig cosmetic product
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- i+Med S.Coop.